Associate Professor/Scientist
University of Ottawa Heart Institute
University of Ottawa Heart Institute
Erin Mulvihill is a scientist at the University of Ottawa Heart Institute and an Associate Professor at the University of Ottawa in the Department of Biochemistry, Microbiology and Immunology. Dr. Mulvihill developed expertise in lipid biology and lipoprotein metabolism completing her Ph.D. in Biochemistry at the University of Western Ontario in the lab of Dr. Murray Huff and gut hormones, dipeptidyl peptidase 4 biology and cardiovascular disease while pursuing post-doctoral research under the mentorship of Dr. Daniel Drucker at the Lunenfeld-Tanenbaum Research Institute. The Mulvihill Lab studies the actions and regulation of the bioactivity of islet and gut hormones. The lab assesses and carefully measures glucose and lipid metabolism aspects in the context of obesity and type 2 diabetes. Her research program generates and utilizes novel mouse models and experimental models of diabetes and obesity to delineate hormone action mechanisms of direct clinical translational relevance. She has received a CIHR New Investigator Award, Heart and Stroke National New Investigator Award, Diabetes Canada New Investigator Award and the CLVS Stewart Whitman New Investigator Award. Her lab is currently funded by CIHR, NSERC, CFI, Heart and Stroke Foundation and Diabetes Canada. Recently, her group identified with Glp1r/Giprβ-cell-/- mice that β-cell incretin receptor signaling is required to mediate the beneficial effects of DPP4 inhibitors on glucose homeostasis. However, DPP4 within the islet does not have a role in regulating the bioactivity of GLP-1 (Fadzeyeva et al., IScience 2023) but liver-derived DPP4 regulates GLP-1 bioactivity in the portal circulation (Trzaskalski JCI Insight, 2023).
Disclosure information not submitted.